Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer

Summary

Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and toxicities in patients with poor risk stage III NSCLC.

Timeline

Start

2009-01

Primary completion

2010-12

Completion

2010-12

Outcome

Outcome not reported

Stopped (Business): “Study terminated due to withdrawal of pharmaceutical funding”

Drugs

Indications